N-phenyl-4-(2-pyridinyl)-1,3-thiazol-2-amine | 315702-76-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-phenyl-4-(2-pyridinyl)-1,3-thiazol-2-amine
• 英文别名: N-phenyl-[4-(2-pyridinyl)thiazole-2-amine]；N-phenyl-4-(pyridine-2-yl)thiazol-2-amine；N-phenyl-4-(pyridin-2-yl)thiazol-2-amine；N-phenyl-4-pyridin-2-yl-1,3-thiazol-2-amine
• CAS: 315702-76-2
• 化学式: C₁₄H₁₁N₃S
• mdl: MFCD01121978
• 分子量: 253.327
• InChiKey: VZHGZKUEVAANEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  440.0±37.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-苯酰基-3-苯基硫脲 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 N-phenyl-4-(2-pyridinyl)-1,3-thiazol-2-amine
  参考文献：
  名称：

  Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

  摘要：

  A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl)-1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 mu M or 0.008 mu g/mL in 7H9 media and therapeutic index of nearly similar to 300. However, 55 is rapidly metabolized by human liver microsomes (t(1/2) = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of similar to 10 (5). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.048

文献信息

• Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents
  作者：Edward A. Kesicki、Mai A. Bailey、Yulia Ovechkina、Julie V. Early、Torey Alling、Julie Bowman、Edison S. Zuniga、Suryakanta Dalai、Naresh Kumar、Thierry Masquelin、Philip A. Hipskind、Joshua O. Odingo、Tanya Parish

  DOI：10.1371/journal.pone.0155209

  日期：——

  designing and synthesizing a large number of analogs and testing these for activity against M. tuberculosis, as well as eukaryotic cells. We determined that the C-2 position of the thiazole can accommodate a range of lipophilic substitutions, while both the C-4 position and the thiazole core are sensitive to change. The series has good activity against M. tuberculosis growth with sub-micromolar minimum

  2-氨基噻唑系列对全球重要病原体结核分枝杆菌具有抗菌活性。我们通过设计和合成大量类似物并测试它们对结核分枝杆菌以及真核细胞的活性来探索其活性的本质。我们确定噻唑的 C-2 位可以容纳一系列亲脂性取代，而 C-4 位和噻唑核心都对变化敏感。该系列对结核分枝杆菌生长具有良好的活性，可达到亚微摩尔的最低抑制浓度。与其他细菌相比，代表性的类似物对分枝杆菌物种具有选择性，并且对复制的结核分枝杆菌具有快速杀菌作用。作用方式似乎不涉及铁螯合。我们的结论是，该系列作为新型抗结核药物具有进一步开发的潜力。
• 4-Pyridylanilinothiazoles That Selectively Target von Hippel−Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death
  作者：Michael P. Hay、Sandra Turcotte、Jack U. Flanagan、Muriel Bonnet、Denise A. Chan、Patrick D. Sutphin、Phuong Nguyen、Amato J. Giaccia、William A. Denny

  DOI：10.1021/jm901457w

  日期：2010.1.28

  recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure−activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in

  肾细胞癌 (RCC) 对预后不良的晚期 RCC 的标准治疗无效；因此，晚期 RCC 的治疗代表了未满足的临床需求。von Hippel-Lindau (VHL) 肿瘤抑制基因在大多数 RCC 中发生突变或失活。我们最近发现了一种 4-pyridyl-2-anilinothiazole (PAT)，它对 VHL 缺陷的肾细胞具有选择性的细胞毒性，这种毒性是通过诱导自噬和增加自溶酶体的酸化来介导的。我们报告了围绕此 PAT 导联的构效关系 (SAR) 的探索。使用成对的 RCC4 细胞系合成并在体外测试三个环中每个环上具有取代基的类似物以及环之间的各种接头。描述不同化学特征对效力的相对空间贡献的等高线图说明了一个区域，与吡啶环相邻，具有进一步发展的潜力。探索这个域的例子验证了这种方法，并可能为开发这种新的化学型作为 RCC 治疗的靶向方法提供机会。
• HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT
  申请人：Turcotte Sandra

  公开号：US20110105436A1

  公开（公告）日：2011-05-05

  Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

  本文提供了新型的杂环芳基化合物、包含这些化合物的组合物以及治疗或预防方法，包括给予这些化合物。这些化合物能够有效地针对von Hippel-Lindau基因缺陷的细胞，并诱导自噬性细胞死亡。这些方法旨在治疗或预防癌症等疾病，特别是由von Hippel-Lindau病引起的癌症。本发明的化合物可以与另一种治疗药物联合使用。
• SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION
  申请人：The Institute for Hepatitis and Virus Research

  公开号：US20140249154A1

  公开（公告）日：2014-09-04

  Pharmaceutical compositions of the invention are presented which comprise substituted aminothiazoles derivatives. The substituted aminothiazoles derivatives have a disease-modifying action in the treatment of diseases associated with unregulated cell growth. Such diseases include cancers such as hepatocellular carcinoma, and viral infections from a hepatitis virus.

  本发明提供了包含取代氨基噻唑衍生物的药物组合物。这些取代氨基噻唑衍生物在治疗与不受调控的细胞生长相关的疾病方面具有疾病修饰作用。这些疾病包括肝细胞癌以及由乙型肝炎病毒引起的病毒感染。
• Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
  申请人：BARUCH S. BLUMBERG INSTITUTE

  公开号：US10087173B2

  公开（公告）日：2018-10-02

  Pharmaceutical compositions of the invention comprise substituted aminothiazoles derivatives having a disease-modifying action in the treatment of diseases associated with unregulated cell growth that include hepatocellular carcinoma, and infection with a hepatitis virus.

  本发明的药物组合物包括具有疾病调节作用的取代氨基噻唑衍生物，可用于治疗与细胞不规则生长有关的疾病，包括肝细胞癌和肝炎病毒感染。